Dynavax Technologies

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 408

Market Cap: $1.4B

Website

Introduction: Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Clinical Trials

Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease

Completed

Conditions: Chronic Kidney Disease

First Posted Date: 2011-01-25

Last Posted Date: 2019-03-20

Lead Sponsor: Dynavax Technologies Corporation

Target Recruit Count: 147

Registration Number: NCT01282762

Locations: 🇺🇸
Clinical Research Associates of Tidewater, Norfolk, Virginia, United States

Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis

Phase 3

Completed

Conditions: End Stage Renal Disease

Interventions: Biological: HEPLISAV
Biological: Engerix-B
Biological: Fendrix

First Posted Date: 2010-09-06

Last Posted Date: 2019-03-20

Lead Sponsor: Dynavax Technologies Corporation

Target Recruit Count: 155

Registration Number: NCT01195246

A Study to Assess DV-601 in Subjects With Chronic Hepatitis B

Phase 1

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: DV-601
Drug: Entecavir

First Posted Date: 2009-12-02

Last Posted Date: 2019-04-16

Lead Sponsor: Dynavax Technologies Corporation

Target Recruit Count: 14

Registration Number: NCT01023230

Locations: 🇵🇱
Collegium Medicum Uniwersytet im. Mikołaja Kopernika, Bydgoszcz, Poland
🇵🇱
NZOZ Centrum Badan Klinicznych, Wrocław, Poland
🇵🇱
Wojewódzki Szpital Zakaźny, Warsaw, Poland

and more 1 locations

Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine

Phase 3

Completed

Conditions: Healthy

Interventions: Biological: HEPLISAV and/or Placebo
Biological: Engerix-B

First Posted Date: 2009-11-01

Last Posted Date: 2019-03-20

Lead Sponsor: Dynavax Technologies Corporation

Target Recruit Count: 2452

Registration Number: NCT01005407

Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients

Phase 3

Completed

Conditions: Chronic Kidney Disease

Interventions: Biological: HEPLISAV-B
Biological: Engerix-B
Other: Placebo

First Posted Date: 2009-09-28

Last Posted Date: 2021-05-19

Lead Sponsor: Dynavax Technologies Corporation

Target Recruit Count: 521

Registration Number: NCT00985426

Locations: 🇺🇸
Clinical Research Associates of Tidewater, Norfolk, Virginia, United States

Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

Phase 1

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: SD-101
Drug: ribavirin

First Posted Date: 2009-01-16

Last Posted Date: 2019-04-16

Lead Sponsor: Dynavax Technologies Corporation

Target Recruit Count: 34

Registration Number: NCT00823862

Locations: 🇵🇱
Wojewódzki Szpital Zakaźny, Warszawa, Poland
🇵🇱
EMC Instytut Medyczny S.A. Szpital Specjalistyczny z Przychodnią "EuroMediCare", Wrocław, Poland
🇵🇱
Klinika Chorób Zakaźnych i Hepatologii Collegium Medicum Uniwersytet Mikołaja Kopernika, Bydgoszcz, Poland

and more 2 locations

Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: placebo
Drug: SD-101

First Posted Date: 2008-01-23

Last Posted Date: 2019-04-16

Lead Sponsor: Dynavax Technologies Corporation

Target Recruit Count: 26

Registration Number: NCT00599001

Locations: 🇺🇸
Healthcare Discoveries, Inc., San Antonio, Texas, United States

An Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber

Phase 2

Completed

Conditions: Rhinitis, Allergic, Seasonal

Interventions: Drug: Histamine
Biological: Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate

First Posted Date: 2007-10-01

Last Posted Date: 2019-04-16

Lead Sponsor: Dynavax Technologies Corporation

Target Recruit Count: 271

Registration Number: NCT00537355

Locations: 🇨🇦
Allied Research International Inc., Mississauga, Ontario, Canada
🇨🇦
Allergy & Asthma Research Centre, Ottawa, Ontario, Canada
🇨🇦
Alpha Medical Research Inc., Mississauga, Ontario, Canada

and more 3 locations

Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine

Phase 2

Completed

Conditions: Hepatitis B

Interventions: Biological: HEPLISAV

First Posted Date: 2007-08-03

Last Posted Date: 2019-04-30

Lead Sponsor: Dynavax Technologies Corporation

Target Recruit Count: 207

Registration Number: NCT00511095

Locations: 🇺🇸
Beeghley Medical Park, Boardman, Ohio, United States
🇺🇸
Family Healthcare Partners, Grove City, Pennsylvania, United States
🇺🇸
Family Practice Medical Associates South, Upper Saint Clair, Pennsylvania, United States

and more 4 locations

A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease

Phase 2

Terminated

Conditions: Hepatitis B

Interventions: Biological: 1018 ISS-HBsAg-Double
Biological: 1018 ISS-HBsAg-Single

First Posted Date: 2007-07-09

Last Posted Date: 2019-03-26

Lead Sponsor: Dynavax Technologies Corporation

Target Recruit Count: 41

Registration Number: NCT00498212

Locations: 🇨🇦
SMBD - Jewish General Hospital, Montreal, Quebec, Canada
🇨🇦
QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦
White Hills Medical Clinic, St Johns, Newfoundland and Labrador, Canada

Home Terms & Conditions Privacy Policy